ibandronic acid actavis 50mg õhukese polümeerikattega tablett
actavis group ptc ehf. - ibandroonhape - õhukese polümeerikattega tablett - 50mg 84tk; 50mg 210tk; 50mg 126tk; 50mg 1tk; 50mg 100tk; 50mg 30tk; 50mg 7tk; 50mg 90tk; 50mg 60tk; 50mg 50tk; 50mg 56tk; 50mg 20tk; 50mg 10tk; 50mg 3tk
ibandronic acid actavis 150mg õhukese polümeerikattega tablett
actavis group ptc ehf. - ibandroonhape - õhukese polümeerikattega tablett - 150mg 3tk; 150mg 1tk; 150mg 30tk; 150mg 7tk; 150mg 21tk; 150mg 14tk; 150mg 10tk; 150mg 20tk; 150mg 28tk
ibandronic acid synthon 50mg õhukese polümeerikattega tablett
synthon b.v. - ibandroonhape - õhukese polümeerikattega tablett - 50mg 30tk; 50mg 168tk; 50mg 126tk; 50mg 28tk; 50mg 10tk; 50mg 42tk; 50mg 100tk; 50mg 56tk; 50mg 14tk; 50mg 7tk; 50mg 60tk; 50mg 50tk; 50mg 210tk; 50mg 21tk
ibandronic acid synthon 150mg õhukese polümeerikattega tablett
synthon b.v. - ibandroonhape - õhukese polümeerikattega tablett - 150mg 3tk; 150mg 10tk; 150mg 14tk
zoledronic acid zentiva 4 mg/ 5 ml infusioonilahuse kontsentraat
zentiva k.s. - zoledroonhape - infusioonilahuse kontsentraat - 4mg 5ml 5ml 5tk; 4mg 5ml 5ml 1tk
ibandronic acid ratiopharm süstelahus süstlis
ratiopharm gmbh - ibandroonhape - süstelahus süstlis - 3mg 3ml 3ml 1tk
ibandronic acid ratiopharm infusioonilahuse kontsentraat
ratiopharm gmbh - ibandroonhape - infusioonilahuse kontsentraat - 6mg 6ml 6ml 5tk; 6mg 6ml 6ml 1tk
dopmin infusioonilahuse kontsentraat
orion corporation - dopamiin - infusioonilahuse kontsentraat - 40mg 1ml 5ml 5tk
clevor
orion corporation - ropinirole vesinikkloriid - dopaminergic ained, dopamiini agonistid - koerad - induktsiooni oksendamine koertel.
upstaza
ptc therapeutics international limited - eladocagene exuparvovec - aminohapete ainevahetus, kaasasündinud vead - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.